Ultragenyx Pharmaceutical Inc RARE
News
-
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
-
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Ultragenyx to Participate in Investor Conferences in September
-
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
-
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
-
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
-
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $54.43
- Day Range
- $53.75–56.22
- 52-Week Range
- $31.52–60.37
- Bid/Ask
- $55.46 / $57.00
- Market Cap
- $5.12 Bil
- Volume/Avg
- 547,361 / 736,329
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.15
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,276
- Website
- https://www.ultragenyx.com
Comparables
Valuation
|
Metric
|
RARE
|
AVIR
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 11.60 | 0.61 | 1.74 |
Price/Sales | 9.15 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
RARE
AVIR
PLRX
Profitability
|
Metric
|
RARE
|
AVIR
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | −31.64% | −23.62% | −27.65% |
Return on Equity (Normalized) | −218.50% | −25.11% | −31.11% |
Return on Invested Capital (Normalized) | −168.31% | −29.21% | −33.69% |
Return on Assets
RARE
AVIR
PLRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Qdjdzmczv | Slrm | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Zblfmqgbq | Fhsgpkg | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Drhznbkrg | Bfnymhg | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ygkbvgthm | Rnkpmq | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Wfjdqgsgp | Kqyy | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Pwgfdlf | Ykcs | $28.1 Bil | |||
| Moderna Inc
MRNA
| Wvnycmwms | Jkz | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Qqrtfjmrm | Ynmdy | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Kfkfgplzt | Hplfxl | $13.4 Bil | |||
| Incyte Corp
INCY
| Wykzdjzcx | Dpnnn | $12.7 Bil |
United States